Last reviewed · How we verify
Placebo for Ocrelizumab
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in clinical trials for Ocrelizumab (multiple sclerosis).
At a glance
| Generic name | Placebo for Ocrelizumab |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in placebo groups are attributed to the placebo effect (psychological and contextual factors) rather than direct drug action. Placebos are essential for blinded trial designs to isolate the true therapeutic benefit of the investigational agent.
Approved indications
- Control arm in clinical trials for Ocrelizumab (multiple sclerosis)
Common side effects
Key clinical trials
- Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis (PHASE4)
- A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PHASE3)
- Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease. (PHASE4)
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (PHASE3)
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (PHASE3)
- Ocrelizumab for Psychosis by Autoimmunity (PHASE1, PHASE2)
- A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis (PHASE3)
- Targeting the Gut Dysbiosis to Treat Inflammation-driven Synaptopathy in MS (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: